# Scientific Exchange onÂ Modeling and Simulation for Radiation Sterilization

Notes compiled from material in [sources/](./sources/).

## Table ofÂ content <!-- omit in toc -->

- [1. Emails from Kola Ladoja and Maggie Gendron](#1-emails-from-kola-ladoja-and-maggie-gendron)
- [2. Notes from Ileana](#2-notes-from-ileana)
- [3. Flip chart A: Operational Qualification (OQ)](#3-flip-chart-a-operational-qualification-oq)
  - [3.1. Medical (patient)](#31-medical-patient)
  - [3.2. Industrial (pallet)](#32-industrial-pallet)
- [4. Flip chart B: Validated simulations toÂ replace dosimetry](#4-flip-chart-b-validated-simulations-toreplace-dosimetry)
- [5. Flip chart C: Risk Analysis for Validating Models](#5-flip-chart-c-risk-analysis-for-validating-models)
  - [5.1. Inaccurate product positioning](#51-inaccurate-product-positioning)
  - [5.2. Difference inÂ am/pm](#52-difference-inampm)
  - [5.3. Model does not represent reality](#53-model-does-not-represent-reality)
  - [5.4. Model has too much complexity](#54-model-has-too-much-complexity)
- [6. Summary fromÂ D. Prieels](#6-summary-fromd-prieels)
  - [6.1. Information](#61-information)
  - [6.2. Technical Committee](#62-technical-committee)
  - [6.3. Target Stakeholder Groups](#63-target-stakeholder-groups)
  - [6.4. Context and Objective](#64-context-and-objective)
  - [6.5. Workshop Summary](#65-workshop-summary)
  - [6.6. Messages](#66-messages)
  - [6.7. Questions](#67-questions)
  - [6.8. Use ofÂ modelling](#68-use-ofmodelling)
  - [6.9. Roadmap and list ofÂ tasks](#69-roadmap-and-list-oftasks)
  - [6.10. Next steps](#610-next-steps)
- [7. Summary from Xun Jia](#7-summary-from-xun-jia)
  - [7.1. Simulation modeling](#71-simulation-modeling)
    - [7.1.1. Current Practice](#711-current-practice)
    - [7.1.2. Modeling and Translation](#712-modeling-and-translation)
    - [7.1.3. Challenges, Concerns, and Areas ofÂ Improvement](#713-challenges-concerns-and-areas-ofimprovement)
  - [7.2. Experience from Radiation Oncology](#72-experience-from-radiation-oncology)
    - [7.2.1. Modeling and Software](#721-modeling-and-software)
    - [7.2.2. Commissioning](#722-commissioning)
    - [7.2.3. QA](#723-qa)
    - [7.2.4. Education and Training](#724-education-and-training)
    - [7.2.5. AAPM Guidelines and Documents](#725-aapm-guidelines-and-documents)
  - [7.3. Possible action items](#73-possible-action-items)
    - [7.3.1. Model Development](#731-model-development)
    - [7.3.2. Use Cases](#732-use-cases)
    - [7.3.3. Delivery Monitoring / QA](#733-delivery-monitoring--qa)
    - [7.3.4. Phantom Development for Commissioning and QA](#734-phantom-development-for-commissioning-and-qa)
    - [7.3.5. Documentation and Regulation](#735-documentation-and-regulation)
- [8. White paper draft byÂ Spencer Mickum](#8-white-paper-draft-byspencer-mickum)
  - [8.1. Information](#81-information)
  - [8.2. Background and Rationale](#82-background-and-rationale)
  - [8.3. Exchange Structure and Key Topics](#83-exchange-structure-and-key-topics)
  - [8.4. Technical Insights and Case Studies](#84-technical-insights-and-case-studies)
  - [8.5. Mock Q-Submission](#85-mock-q-submission)
  - [8.6. Radiation Oncology Parallels](#86-radiation-oncology-parallels)
  - [8.7. Regulatory Perspectives](#87-regulatory-perspectives)
  - [8.8. Outcomes and Roadmap](#88-outcomes-and-roadmap)
  - [8.9. Conclusion](#89-conclusion)
- [9. Summary from Ileana Pazos](#9-summary-from-ileana-pazos)
  - [9.1. Information](#91-information)
  - [9.2. Overview](#92-overview)
    - [9.2.1. Workshop Structure and Participants](#921-workshop-structure-and-participants)
    - [9.2.2. Key Problem Identified](#922-key-problem-identified)
  - [9.3. â€œSameâ€ Problem, except for dose and scale](#93-same-problem-except-for-dose-and-scale)
    - [9.3.1. Focused clinical beam (2 GyÂ toÂ ~1 cmÂ region)](#931-focused-clinical-beam-2-gyto1-cmregion)
    - [9.3.2. Large-scale processing (20 kGy toÂ ~1 mÂ region)](#932-large-scale-processing-20-kgy-to1-mregion)
  - [9.4. Stakeholders: 47 registrants, 30 organizations](#94-stakeholders-47-registrants-30-organizations)
    - [9.4.1. Academia](#941-academia)
    - [9.4.2. Government](#942-government)
  - [9.5. Industry: Testing, Standards and Certification](#95-industry-testing-standards-and-certification)
    - [9.5.1. Industry: Medical Devices and Healthcare](#951-industry-medical-devices-and-healthcare)
    - [9.5.2. Industry: Radiation Processing and Sterilization](#952-industry-radiation-processing-and-sterilization)
  - [9.6. Major Outcomes and Consensus](#96-major-outcomes-and-consensus)
  - [9.7. Technical Requirements Identified](#97-technical-requirements-identified)
  - [9.8. Action Items](#98-action-items)
    - [9.8.1. Foundational](#981-foundational)
    - [9.8.2. Strategic Development](#982-strategic-development)
    - [9.8.3. Communication and Engagement](#983-communication-and-engagement)
  - [9.9. Challenges and Limitations](#99-challenges-and-limitations)
  - [9.10. White paper outline: Enhancing the Credibility ofÂ Simulation inÂ Sterilization](#910-white-paper-outline-enhancing-the-credibility-ofsimulation-insterilization)
    - [9.10.1. Executive Summary](#9101-executive-summary)
    - [9.10.2. Introduction and Context](#9102-introduction-and-context)
    - [9.10.3. Overview ofÂ the Discussion](#9103-overview-ofthe-discussion)
    - [9.10.4. Prioritizing Key Elements for aÂ Roadmap](#9104-prioritizing-key-elements-for-aroadmap)
    - [9.10.5. Developing aÂ Practical Roadmap](#9105-developing-apractical-roadmap)
    - [9.10.6. Building Credibility with Regulators](#9106-building-credibility-with-regulators)
    - [9.10.7. Leveraging Existing Resources and Standards](#9107-leveraging-existing-resources-and-standards)
    - [9.10.8. Developing aÂ Use Case and Working Group](#9108-developing-ause-case-and-working-group)
    - [9.10.9. Engaging the Academic Community](#9109-engaging-the-academic-community)
    - [9.10.10. Final Thoughts and Next Steps](#91010-final-thoughts-and-next-steps)
- [10. Summary from Spencer Mickum](#10-summary-from-spencer-mickum)
  - [10.1. Information](#101-information)
  - [10.2. Scientific Exchange Highlights](#102-scientific-exchange-highlights)
    - [10.2.1. Interdisciplinary Collaboration](#1021-interdisciplinary-collaboration)
    - [10.2.2. Consensus and Roadmap Development](#1022-consensus-and-roadmap-development)
    - [10.2.3. Agenda](#1023-agenda)
  - [10.3. Technical Insights and Case Studies](#103-technical-insights-and-case-studies)
    - [10.3.1. Functional Equivalence](#1031-functional-equivalence)
    - [10.3.2. Modeling vsÂ Physical Testing](#1032-modeling-vsphysical-testing)
    - [10.3.3. Real-world Application Examples](#1033-real-world-application-examples)
  - [10.4. Regulatory Insights and Modeling](#104-regulatory-insights-and-modeling)
    - [10.4.1. Modeling asÂ Regulatory Evidence](#1041-modeling-asregulatory-evidence)
    - [10.4.2. Standards and Programs](#1042-standards-and-programs)
    - [10.4.3. Simulation for Compliance and Innovation](#1043-simulation-for-compliance-and-innovation)
  - [10.5. Outcomes and Future Roadmap](#105-outcomes-and-future-roadmap)
    - [10.5.1. Consensus onÂ Standardization](#1051-consensus-onstandardization)
    - [10.5.2. Identified Key Barriers](#1052-identified-key-barriers)
    - [10.5.3. Action Plan for Advancement](#1053-action-plan-for-advancement)
- [11. Summary from Cody Wilson](#11-summary-from-cody-wilson)
  - [11.1. Breakout session on Traceability and Validation](#111-breakout-session-on-traceability-and-validation)
    - [11.1.1. Enhancing and Replacing Dosimetry and Validation Activities](#1111-enhancing-and-replacing-dosimetry-and-validation-activities)
    - [11.1.2. Supporting Parametric Release and Routine Operations](#1112-supporting-parametric-release-and-routine-operations)
    - [11.1.3. Advancing Regulatory Submission and Standardization](#1113-advancing-regulatory-submission-and-standardization)
  - [11.2. Breakout session on establishing confidence in models](#112-breakout-session-on-establishing-confidence-in-models)
    - [11.2.1. Address Product Positioning Risk](#1121-address-product-positioning-risk)
    - [11.2.2. Ensure System State Monitoring](#1122-ensure-system-state-monitoring)
    - [11.2.3. Improve Model Accuracy](#1123-improve-model-accuracy)
    - [11.2.4. Define Model Limits](#1124-define-model-limits)
  - [11.3. Breakout session onÂ Embedding Reality into Models](#113-breakout-session-onembedding-reality-into-models)

## 1. Emails from Kola Ladoja and Maggie Gendron

```yaml
From: Logar, John
Sent: September 24, 2025 16:21
Subject: NIST Scientific Exchange onÂ M&S for radiation sterilization.
```

See below â€” one ofÂ the attendees forwarded meÂ this information asÂ something toÂ consider asÂ weÂ look for funding.

```yaml
From: Kola Ladoja
Date: Wednesday, September 24, 2025 atÂ 4:02â€¯PM
Subject: NIST Scientific Exchange onÂ M&S for radiation sterilization.
```

Thank you for the invitation toÂ the Scientific exchange last week. MyÂ colleague and IÂ learnt aÂ lot and met some wonderful people.

With regard toÂ the funding challenge raised toward the end ofÂ the exchange. IÂ made anÂ internal inquiry about the â€œcongressional addâ€ idea and got some information that might beÂ ofÂ use toÂ CIRMS/NIST. Please see the email below from myÂ colleague. She provides aÂ recommendation and possible contacts.

Thank you and good luck!

```yaml
From: Maggie Gendron
Sent: Tuesday, September 23, 2025 10:57 AM
Subject: Follow-up from our coffee chat
```

HiÂ there,

IÂ work mostly with the Senate Labor Health and Human Services subcommittee onÂ appropriations â€“ and the leadership isÂ Senator Shelly Moore Capito ofÂ West Virginia and Ranking member Senator Tammy Baldwin ofÂ Wisconsin. ARA isÂ lucky inÂ that weÂ have aÂ footprint inÂ both ofÂ those states, and several members ofÂ the committee are also friends ofÂ ARA.

OnÂ the civilian side, weÂ call â€œcongressional addsâ€ something else. They call them Congressionally Directed Spending. However, the rules are very different inÂ non-defense than defense, and noÂ private for profit company can receive congressionally directed spending. ItÂ has toÂ beÂ anÂ academic institution orÂ aÂ non-profit orÂ other government service.

The kinds ofÂ funding you would pursue for your modelling and simulation concept would beÂ through the Department ofÂ Health and Human Services, Health Resources and Services Administration fund.

InÂ the case your association ofÂ stakeholders has partners inÂ these locations â€“ this isÂ one lab that received significant funding inÂ 2025 and pending 2026:

- Marshall University Medical Simulation Center and Laboratory inÂ West Virginia (this isÂ mostly for nursing and medical training)

The other way toÂ get your foot inÂ the door isÂ toÂ develop aÂ relationship with the FDA and beÂ aÂ part ofÂ this conversation:

- FDAâ€™s Actions toÂ Advance Medical Device Sterilization

  The FDA isÂ actively working with sterilization experts, medical device manufacturers, and other government agencies toÂ advance innovative ways toÂ sterilize medical devices with lower levels ofÂ currently used agents, and employ new agents orÂ alternatives, while maintaining device safety and effectiveness.

InÂ 2019, the FDA did host aÂ technology challenge looking for new methodologies toÂ device sterilization and there might beÂ aÂ way toÂ make anÂ argument toÂ ehÂ FDA now onÂ modeling and simulation improvements for efficiency.

SoÂ â€“ all toÂ say, IÂ donâ€™t think the congressionally directed spending space isÂ one toÂ head toward first, rather develop aÂ relationship inside FDA and these are some places toÂ start:

These folks existed previous toÂ 2025, and may still beÂ around (ifÂ your partners have any relationships with the below):

- Dr. Aftin Ross, Deputy Director ofÂ the Office ofÂ Readiness and Response within the CDRHâ€™s Office ofÂ Strategic Partnerships and Technology Innovation, orÂ OST;
- Christopher Dugard, Assistant Director for Sterility Devices inÂ the Office ofÂ Health Technology inÂ the Office ofÂ Product Evaluation and Quality, orÂ OPEQ;
- Dr. Tammy Beckham, Director ofÂ the Office ofÂ Supply Chain Resilience inÂ OST;
- Dr. Ryan Ortega, Regulatory Advisor onÂ the Regulatory Policy and Combination Products staff within OPEQ

## 2. Notes from Ileana

```yaml
From: Pazos, Ileana
Sent: September 25, 2025 0:02
Subject: Summary ofÂ exchange
```

These are notes from the day 1 breakout.

The meeting focused onÂ advancing modeling inÂ radiation processing, discussing validation techniques, parametric release, and regulatory submissions. Key points included the importance ofÂ dosimetry, the potential for models toÂ replace physical measurements, and the need for sensitivity analyses. The group proposed using standardized libraries for different materials and geometries toÂ enhance credibility. They also discussed the ASTM E61 proficiency test and the concept ofÂ digital twins for sterilization. The session concluded with plans for case studies and action items, emphasizing collaboration and the development ofÂ practical models.

- Develop aÂ model for photon-based radiation processing that can account for uncertainties and sensitivities.

- Assemble aÂ sufficient ground truth data set, including independently designed engineer phantoms, toÂ validate the modelâ€™s accuracy.

- Explore the use ofÂ aÂ master file submission toÂ the FDA asÂ aÂ way toÂ introduce more flexibility inÂ regulatory approvals.

- Focus onÂ class 2 products asÂ aÂ starting point for building the ground truth data and validating models.

- Investigate the feasibility ofÂ creating aÂ standardized phantom orÂ test setup toÂ help validate models and understand the sensitivity ofÂ dosimetry measurements.

## 3. Flip chart A: Operational Qualification (OQ)

![flipchart-a.jpg](./assets/flipchart-a.jpg)

### 3.1. Medical (patient)

- OQÂ vsÂ IQ
- TG-51
- Everyone does itÂ the same way
- Chamber + Phantom

### 3.2. Industrial (pallet)

- NoÂ universal standard
- ASTM 51649
- NoÂ PT
- NoÂ collaboration between facilities
- IBA acceptance testing, facility-driven
- Dose map submitted toÂ regulator
- Co-60 OQÂ after loading
- Approval for each product (performance envelope)
- What simulations can bring: PQÂ (Process Qualification)
- Electron beam (e-beam): better for modeler
- Accuracy ofÂ input data?
- Low-hanging fruit: Photons
- Variability study: virtually shake the box!

## 4. Flip chart B: Validated simulations toÂ replace dosimetry

![flipchart-b.jpg](./assets/flipchart-b.jpg)

- Low-hanging fruit
- Try everything, achieve nothing?
- Pallet: standard irradiator JS-1000 (Gamma), 20â€“30 units
- Class IIÂ (not Class III)
- Photon (X-ray)
- +/- 1.5 kGy Sterility Assurance Level (SAL) increase
- 5% cannot increase itÂ (hurts efficiency)
- 90% 200â€“300 Gy
- 24.9 kGy: product rejection
- DoÂ weÂ know all uncertainties connected toÂ simulation?
  - Coefficient for water isÂ well-known
  - What about interaction coefficient for random material?
- Gain confidence (answer not known)
- Not sensitive toÂ material composition
- Regulatory hurdle, what toÂ get rid of?
- Avoid FDA filing for aÂ new installations
- Master file Gamma toÂ X-ray
- Simulation + dosimetry side-by-side
- PAT (Process Analytics Techniques)
- InÂ radiation therapy: QAÂ daily, quarterly, yearly
- Proficiency
- Parametric release, no-routine
- FDA â€œReduce regulatory burdenâ€
- During OQ, during PQ, periodicity (testing regularly)
- Routine dosimetry â€œIÂ donâ€™t like itâ€
- Florentâ€™s dream: Modelling asÂ primary standard, relative simulation toÂ compare toÂ geometry

## 5. Flip chart C: Risk Analysis for Validating Models

![flipchart-c.jpg](./assets/flipchart-c.jpg)

### 5.1. Inaccurate product positioning

**Mitigation:**

- CTÂ scans ofÂ realistic product
- Not capturing the extreme
- Triplicate dosimetry
- Simulate all variations
- Dose insight â€” shake the box
- Sensitivity analysis â€” find extremes

### 5.2. Difference inÂ am/pm

**Mitigation:**

- OQÂ inÂ am
- OQÂ inÂ pm
- Monitor both

### 5.3. Model does not represent reality

**Mitigation:**

- Ground truth data
- Use simple and standard phantom
- Simple toÂ complex

### 5.4. Model has too much complexity

- Ground truth data
- Use simple and standard phantom
- 3D CAD print with dosimeter

## 6. Summary fromÂ D. Prieels

### 6.1. Information

- September 16â€“17, 2025, NIST Gaithersburg Campus, Gaithersburg, Maryland
- This event was co-hosted byÂ **NIST**Â and the **Council onÂ Ionizing Radiation Measurements and Standards (CIRMS)**.
- [Event Page](https://www.nist.gov/news-events/events/2025/09/scientific-exchange-modeling-and-simulation-radiation-sterilization)

### 6.2. Technical Committee

- John Logar â€” J&J
- Cody Wilson â€” IBA
- Xun Jia â€” John Hopkins
- Ileana Pazos â€” NIST
- Spencer Mickum â€” STERIS
- Frederic Tessier â€” NRC Canada (absent)
- Shaheen Dewji â€” Georgia Institute ofÂ Technology

### 6.3. Target Stakeholder Groups

- Healthcare Companies
- Radiation Therapy Companies
- Sterilization Companies
- Regulatory Agencies
- Notified Bodies
- Academic Institutions
- Industry Associations â€” CIRMS, ASTM (E61), The Irradiation Panel, AAPM

### 6.4. Context and Objective

Despite the growing potential ofÂ mathematical modeling and simulation toÂ transform industrial radiation sterilization, widespread adoption remains limited. This stems not from technical constraints, but from aÂ lack ofÂ shared scientific frameworks, standardized verification methods, and clear quality assurance processes. AsÂ aÂ result, modeling isÂ often seen asÂ supplementary rather than foundational, and industries continue toÂ rely heavily onÂ costly, time-intensive physical testing.

ToÂ address these challenges, this 2-day scientific exchange will bring together aÂ diverse coalition ofÂ stakeholders from industry, academia, standards organizations, and the public sector. The event, co-hosted byÂ the National Institute ofÂ Standards and Technology (NIST) and the Council onÂ Ionizing Radiation Measurements and Standards (CIRMS) isÂ designed toÂ foster critical dialogue and collaboration around building the scientific infrastructure needed toÂ elevate modeling and simulation into trusted components ofÂ sterilization workflows.

Participants will explore how rigorous practices from adjacent fieldsâ€”most notably radiation therapyâ€”can beÂ adapted toÂ meet the specific needs ofÂ sterilization. The exchange will examine current modeling approaches, validation techniques, and digital toolchains, and will identify technical gaps and barriers that hinder broader acceptance. Key topics include model verification and validation, uncertainty quantification, round-robin intercomparisons, traceability toÂ standards, and the role ofÂ metrology inÂ underpinning trustworthy simulation outputs.

### 6.5. Workshop Summary

The following goals were highlighted during the introductory talks:

- Assessâ€¦
- Review best practices inÂ model validation
- Identify needs inÂ fixture development, uncertainty quantification, cross validation
- Explore how standards / guidance documents can support acceptance
- Inform the next edition ofÂ the CIRMS needs report toÂ help guide NISR priorities inÂ this area

### 6.6. Messages

The following messages were mentioned during the talks ofÂ the plenary sessions:

- J. Meissner: WeÂ demonstrated the value ofÂ modelling long time ago (RPSMUG 2002, simulation ofÂ CAPA \[Abbott\] inÂ 2013) and standards are inÂ place (ex: E2232-10 inÂ 2000, ASTM E1649 \[now 51649\])

- J. Meissner: Modelling can reduce time and cost for product design

- S. Mickum:
  - Modelling isÂ used inÂ many areas (flight simulator, aerodynamics, air quality, etc.) and help improve design / take right decision).
  - InÂ Medicine, itÂ isÂ used more and more (orthopaedics, cardiology, etc.).
  - Compared toÂ traditional method, simulation allows cost effectiveness, Time efficiency, Safety and risk reduction, Richness ofÂ data and Insights.
  - Regulatory bodies actively promotes and recognize the value ofÂ CM&S asÂ part ofÂ the evidence package for device approval and clearance

- P. Afshiri showed aÂ great example ofÂ the use ofÂ modeling toÂ get FDA clearance for the use ofÂ MRI onÂ patient having metallic implants. Solving the problem would not have been possible without simulation

- S. Mickum: IsÂ modeling credible for its intended use?

- S. Mickum: What tolerance are appropriate?

- S. Mickum: Best practices:

  - â€œReporting ofÂ Computational Modeling Studies inÂ Medical Device Submissions -- Guidance for Industry and FDAâ€, 2016 ([Reporting ofÂ Computational Modeling Studies inÂ Medical Device Submissions - Guidance for Industry and Food and Drug Administration Staff](https://www.fda.gov/media/87586/download))

  - 2 other reports mentioned byÂ Spencer.

- J. Logar: Collaboration with the regulators toÂ decide onÂ the acceptance criteria allow great time saving when itÂ comes toÂ demonstrate functional equivalence inÂ anÂ effort toÂ reduce requalification (ex: TyvekÂ® from Dupontâ„¢).

- J. Logar: Inactivation isÂ anÂ inaccurate science, ItÂ should not beÂ hard toÂ have confidence inÂ modeling.

- S. Mickum: The standards doÂ not define the number ofÂ dosimeters inÂ aÂ dose mapping, while simulation allows toÂ get dose atÂ any point ðŸ¡º one could reduce the number ofÂ dose mappings and improve the final results.

- InÂ RT, the trust the simulation (the dose isÂ defined byÂ the TP). The patient QAÂ isÂ not asÂ accurate. ItÂ isÂ just there toÂ detect error! InÂ RP, what isÂ critical isÂ toÂ beÂ sure ofÂ the transfer ofÂ the product into the modelling software (J. Logar).

- D. Mihailidis: the Therapy Physics Committee (TPC) from AAPM achieves the following goals through its Subcommittees, Working Groups and Task Groups (TG):

  - Improve accuracy and consistency ofÂ RTÂ through development and publication ofÂ scientific, technical and educational documents

  - Improve medical interventions through research and promote research inÂ therapy applications ofÂ medical physics

  - Provide guidance toÂ outside agencies and organizations relative toÂ the scientific and clinical interest ofÂ AAPM membership

  - Remain aware ofÂ developments from and collaborate with outside organizations.

- Regulator: the information required byÂ the FDA depends onÂ product type. For instance, the FDA isÂ less demanding for Class IIÂ products than for class III products (where complete IQ, OQ, PQÂ data are requested).

- Advice from FDA onÂ how/what toÂ present inÂ the submission file:

  - Say that you are not changing anything. Just taking advantage ofÂ the great tool.

  - Show the protocol.

  - Show you doÂ not model anything different than what isÂ being done.

  - Show trends.

  - Show uncertainties.

  - Show what itÂ would doÂ toÂ patient. Alos remember that the type/depth ofÂ info will drive the question from FDA â‡’ doÂ pre-discussion with FDA toÂ clarify what should beÂ shown inÂ order toÂ have aÂ regulatory-technical discussion (and not aÂ scientific discussion)!

- Regulator: FDA claim they would beÂ proactive, ifÂ weÂ are inÂ line and ifÂ weÂ are confident inÂ what weÂ are simulating â‡’ our confidence isÂ important: â€œ*You should build confidence with the regulator. ToÂ doÂ so, the community should talk asÂ one voice*!â€

- S. Mickum: RayXpert isÂ validated. Validation includes benchmarking with MCNP 6.2, GEANT4 and published scientific literature for accuracy

- WeÂ should aim atÂ functional equivalence (with well defined source)

- About CTÂ images for simulation:

  - E. Carvan: Having on-line imaging would beÂ aÂ beautiful innovation

  - Ayeh mentions aÂ sensitivity analysis isÂ important inÂ EBÂ (exÂ toÂ see sensitivity toÂ film packaging placement). Tobias highlights that this isÂ not capture today with dosimetry!

- J. Logar: Actual dose isÂ way too conservative!

### 6.7. Questions

The following questions were raised during the talks ofÂ the plenary sessions:

- S. Mickum: IsÂ modeling credible for its intended use?

- S. Mickum: What tolerances are appropriate?

- Group C: 5% tolerance inÂ RT. Does itÂ apply inÂ RP?

- Group CÂ + J. Logar: What isÂ important: accurate orÂ credible model? DoÂ weÂ want anÂ exact model orÂ aÂ functional equivalent model?

- Group C: Can simulation beÂ considered compliant without validation? Quid relative vs. absolute?

### 6.8. Use ofÂ modelling

During the workshop, four cases were discussed where modeling could beÂ helpful for the RPÂ community. IÂ gathered them inÂ the following 2Ã—2 matrix:

| | Would not require regulatory approval / standard changes inÂ standard | Would requires regulatory approval / standard changes inÂ standard |
|: ------------------------ |: -------------------------------------------------------------------------------------------------------- |: ----------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Product Design** | Rapid iteration and failure detection + Reduce time-to-market + reduce cost (prototype, Case study, etc.) | |
| **Product qualification** | PQÂ dose mapping: helps placing dose. Save time, more efficient ðŸ¡º Improved patient safety | Demonstrate functional equivalence inÂ anÂ effort toÂ reduce requalification; PQÂ dose mapping: replace partly (orÂ totally?) physical dose mappings byÂ VDM |

### 6.9. Roadmap and list ofÂ tasks

The three working groups worked onÂ anÂ action plan. The define the tasks that would beÂ needed toÂ move forward and have CM&S efficiently used inÂ the RPÂ community. IÂ collected the following list:

- Why simulation? What isÂ the value proposition/benefits for the patient and for the businesses ofâ€¦

  - removing dosimetry?
  - getting next product being approved faster?
  - all what IÂ could doÂ with modeling?

- Build **confidence for the regulator**

  - **FDA: Talk asÂ one voice**
  - form aÂ community ofÂ user.
  - Aligned consensus.
  - Phantoms,

- Quantify uncertainty â‡’ Uncertainty mgt

- Phantom / standard model

- Control ofÂ process:

  - What confidence inÂ control? Need toÂ show that you really understand each step
  - FDA does not only look atÂ the perceived risk, but the perceived control

- Start with photons:

  - Photons isÂ mainly what weÂ doÂ today
  - but the LTÂ benefits maybe for EB

- Technical translation

  - Speak language everybody understand.
  - Translate inÂ simplistic terms
  - Ex: BPSA

- Benchmarking / translation data:

  - DP: inter-comparison onÂ aÂ standard model. Tobias likes complex model that represents reality (ex: syringes instead ofÂ cylinder)
  - Leo: BPSA model

- Design process integration (simulation for R&D)

- Modeling expertise: Competency? What needs toÂ beÂ aÂ good modeler?

- Lust ofÂ validated and approved tools

- Bringing confidence

  - COP orÂ better: aÂ program
  - \>< RT, they have accredited medical physicists.

- Upfront integration

Work group AÂ discussed the possible contribution ofÂ existing groups:

- Universities

- The Irradiation Panel

  - Uncertainty mgt
  - Phantom / standard model
  - Competency? What needs toÂ beÂ aÂ good modeler?
  - Control ofÂ process -

- KILMER (AAMI)

  - J. Logar doesnâ€™t believe there isÂ much value there now (more focus onÂ Âµ-biology)

- CIRMS

  - Get funding
  - Benefits paper (white paper)

- IIA and IAEA:

  - Webinars toÂ raise awareness
  - Tech Doc

- ASTM

  - Collaboration with Panel
  - From PQÂ toÂ modelling. How doÂ you demonstrate the control?
  - Beam model

- AAPM (same physics, comes from high energy. FDA confirms itÂ could help)

  - Technical translation

- NIST:

  - Control ofÂ the process / Traceability ofÂ the model

- Radiation Research Society

- ASME

Group AÂ discussed also possible opportunities for funding:

- NNSA

- Consortium ofÂ companies (see benefits)

- Dpt ofÂ congress

- Other dedicated grant funding

### 6.10. Next steps

- **J. Logar send anÂ invitation toÂ contribute toÂ everyone: â€œSend your ideas. DoÂ you want toÂ contribute toÂ one action item?â€**

- J. Logar commits toÂ write aÂ white paper around this WS

- J. Logar leads the group toÂ write the benefits.

## 7. Summary from Xun Jia

### 7.1. Simulation modeling

#### 7.1.1. Current Practice

- **Beam energy and modality:** Most facilities use **4â€“10 MeV electron beams** either directly for irradiation orÂ toÂ generate bremsstrahlung x-rays.

  - **Electron beams are generally preferred** because they offer higher throughput and efficiency for bulk processing.

- **Dosimetry methods:** Dose distribution isÂ typically verified using **film** orÂ **alanine**, placed around orÂ within the phantom/pallet.

  - These measurements provide spatial mapping but may beÂ limited inÂ representing highly heterogeneous setups.

- **Dose targets:** The operational goal isÂ toÂ achieve consistent dosing, with the **maximum dose capped atÂ ~40 kGy** and the **minimum threshold atÂ ~25 kGy**, ensuring regulatory compliance and effective sterilization while avoiding overexposure.

#### 7.1.2. Modeling and Translation

- **Monte Carlo (MC) simulations** are widely considered the gold standard for predicting 3D dose distributions inÂ complex geometries.

  - They provide confidence inÂ accounting for scatter, heterogeneities, and secondary particle effects.

- For practical adoption, there needs toÂ beÂ aÂ **clear translation path**: demonstrating how MCÂ modeling results can beÂ systematically integrated into **industrial workflows**, validated against real-world measurements, and accepted byÂ regulatory authorities.

#### 7.1.3. Challenges, Concerns, and Areas ofÂ Improvement

- **Simulation configuration and flexibility:**

  - Each facility operates with **unique irradiation configurations** (beam energy, scanning patterns, conveyor geometry, shielding).

  - Simulation frameworks must allow **customizable setups** soÂ results are relevant across sites.

- **Beam model quality:**

  - Current practice often depends onÂ **vendor-supplied beam models/data**, which may not capture real operational variability.

  - There isÂ aÂ need for **independent verification ofÂ accuracy and stability** ofÂ beam models over time.

  - AÂ formal **commissioning process for the MCÂ dose engine**â€”similar toÂ clinical radiotherapyâ€”would strengthen confidence.

- **Phantom and material representation:**

  - Processing objects are highly heterogeneous, including **polymers, plastics, electronics, and packaging materials** etc.

  - Accurate geometry and material assignment isÂ challenging:

  - **CAD files may not exist, orÂ may beÂ outdated/inaccurate.**

  - Simplifications may lead toÂ deviations inÂ predicted dose.

  - **CT imaging** could beÂ used toÂ capture more accurate geometry and density information, though feasibility and throughput remain questions.

- **Geometry uncertainties:**

  - **Motion orÂ shifting ofÂ objects** during conveyor transfer can alter dose delivery, which isÂ not always accounted for inÂ simulations.

- **Physics modeling atÂ heterogeneous interfaces:**

  - Dose near **material boundaries** isÂ difficult toÂ model due toÂ **electron disequilibrium effects**.

  - Experimental measurement isÂ also limited inÂ such regions, asÂ film orÂ alanine may not fully represent small-scale variations.

  - This remains aÂ critical source ofÂ uncertainty when validating models against measurements.

### 7.2. Experience from Radiation Oncology

#### 7.2.1. Modeling and Software

- **Material definition:** InÂ clinical radiotherapy, careful consideration isÂ given toÂ patient anatomy and tissue composition. ItÂ isÂ important knowing **to what extent accuracy inÂ geometry and material properties truly impacts dose calculation outcomes**, enabling prioritization between detailed modeling and practical efficiency.

- **Beam modeling:** Radiotherapy requires thorough **beam commissioning** toÂ characterize effective beam properties, including **energy spectrum, fluence distributions, and contamination from secondary photons and electrons**. This process ensures models are not blindly dependent onÂ vendor data but instead reflect measured clinical reality.

- **Transport physics:** Accurate modeling ofÂ **electron transport atÂ interfaces** isÂ critical, especially inÂ regions ofÂ disequilibrium such asÂ air cavities orÂ tissueâ€“bone interfaces. Radiation oncology has developed methodologies toÂ both calculate and experimentally validate these effects.

- **Computational efficiency:** Clinical practice has benefited from **GPU-based, dedicated dose calculation engines** (work atÂ JHU) toÂ achieve near real-time dose computation without sacrificing accuracy. This experience demonstrates how advanced hardware/software co-design can bring Monte Carlo methods into routine workflows.

- **User interface:** Radiotherapy software isÂ designed toÂ beÂ used safely byÂ **non-Monte Carlo experts**, with error-proof interfaces and guardrails toÂ prevent misuse. This isÂ critical toÂ broaden access while maintaining accuracy and safety.

#### 7.2.2. Commissioning

- Radiation oncology mandates **independent verification** ofÂ vendor-provided beam and geometry specifications before clinicalÂ use. Measurements with calibrated detectors are used toÂ establish commissioning data sets that serve asÂ the baseline for ongoingÂ QA. This process underscores the need for rigorous commissioning inÂ any dose modeling system.

#### 7.2.3. QA

- Comprehensive QAÂ protocols are embedded atÂ **daily, monthly, and annual** intervals toÂ ensure beam stability, system accuracy, and overall treatment safety.

- QAÂ equipment itself must beÂ **regularly calibrated and verified**, ensuring consistency across time and between institutions.

- **Dose traceability** isÂ important, with ionization chambers and dosimeters calibrated against NIST-traceable standards, ensuring universal comparability and regulatory compliance.

#### 7.2.4. Education and Training

- The field defines clear **qualifications for dose calculation and measurement personnel**, embodied inÂ the role ofÂ the **Qualified Medical Physicist (QMP)**. This ensures that only properly trained professionals assume responsibility for critical tasks.

- Standardized **accreditation and regulation pathways** exist for training programs (e.g., **CAMPEP**), professional practice (e.g., **ABR board certification**). Similarly, software and equipment are regulated through bodies such asÂ the **FDA**.

#### 7.2.5. AAPM Guidelines and Documents

- The **American Association ofÂ Physicists inÂ Medicine (AAPM)** has produced anÂ extensive library ofÂ task group (TG) reports and practice guidelines. These provide detailed recommendations for modeling, commissioning, QA, and education, serving asÂ authoritative standards. Industrial irradiation efforts could similarly benefit from consensus documents developed byÂ professional societies.

- TGÂ reports can beÂ adapted

### 7.3. Possible action items

#### 7.3.1. Model Development

- Build aÂ **prototype software platform**â€”simple but functionalâ€”to serve asÂ aÂ proof ofÂ principle.

- Incorporate aÂ **commissioning and QAÂ framework** similar toÂ clinical radiotherapy, demonstrating feasibility and reliability ofÂ dose modeling for industrial irradiation.

#### 7.3.2. Use Cases

- Apply the developed model toÂ show feasibility and advantages, **build business cases**, why weÂ move towards this direction.

- Apply the developed model toÂ evaluate **uncertainties due toÂ motion, geometry, positioning, and orientation**, and investigate what levels ofÂ uncertainty are acceptable versus achievable.

- Perform **retrospective dose reconstruction** for products processed atÂ one orÂ more irradiation facilities toÂ quantify dose variation inÂ real-world practice.

  - Use results toÂ identify **areas for improvement** (e.g., where modeling orÂ process control isÂ needed) and **areas where requirements can beÂ relaxed** without compromising outcomes.

#### 7.3.3. Delivery Monitoring / QA

- Leverage **x-ray projection imaging** ofÂ pallets/products during irradiation toÂ reconstruct contents and detect **gross errors** such asÂ incorrect orientation, major motion, orÂ substitution ofÂ content.
- Develop workflows for integrating these monitoring steps into **routine QAÂ and process validation**.

#### 7.3.4. Phantom Development for Commissioning and QA

- Design and fabricate **standard phantoms** for both commissioning and routine QA:

  - **Homogeneous phantom** (with aÂ suitable reference material, TBD) containing embedded dosimeters/chambers toÂ allow 3D dose verification, confirming beam modeling and dose calculation accuracy inÂ aÂ uniform medium.

  - **Layered phantom** with representative materials toÂ validate dose calculation accuracy inÂ heterogeneous geometries.

  - **Semi-realistic pallet phantom**, mimicking typical product composition and configuration, toÂ enable **end-to-end system verification**.

#### 7.3.5. Documentation and Regulation

- Conduct aÂ **review ofÂ AAPM Task Group (TG) reports**, focusing onÂ parallels between radiation oncology and industrial irradiation.

- Develop aÂ **comparative framework** that identifies which TGÂ recommendations are directly applicable, which require adaptation, and where new guidance isÂ needed.

- Use findings toÂ inform the creation ofÂ **regulatory and best-practice documents** that can beÂ adopted byÂ the field.

## 8. White paper draft byÂ Spencer Mickum

### 8.1. Information

- **Scientific Exchange onÂ Modeling and Simulation for Radiation Sterilization**
- White Paper Summary
- September 16--17, 2025
- NIST Gaithersburg Campus

### 8.2. Background and Rationale

The Scientific Exchange onÂ Modeling and Simulation for Radiation Sterilization, held atÂ the NIST Gaithersburg campus inÂ September 2025, brought together aÂ diverse group ofÂ stakeholders from industry, academia, regulatory agencies, and standards organizations. The central challenge addressed atÂ this event was the limited adoption ofÂ mathematical modeling and simulation inÂ routine industrial radiation sterilization workflows, despite their proven value inÂ related fields such asÂ radiation therapy. The exchange was co-hosted byÂ the National Institute ofÂ Standards and Technology (NIST) and the Council onÂ Ionizing Radiation Measurements and Standards (CIRMS), with the explicit aim ofÂ advancing consensus and developing aÂ roadmap for robust, traceable modeling practices.

The rationale for convening this exchange stemmed from the recognition that, while modeling and simulation are integral toÂ high-reliability industries, their use inÂ sterilization isÂ hampered byÂ aÂ lack ofÂ standardized guidance, scientific consensus, and quality assurance infrastructure. The absence ofÂ clear frameworks for verification, validation, and uncertainty quantification has led toÂ inconsistent practices and diminished confidence inÂ modeling asÂ aÂ supplement orÂ alternative toÂ physical testing. The event sought toÂ bridge these gaps byÂ fostering dialogue among technical experts, healthcare product manufacturers, sterilization contractors, standards developers, and academic institutions.

### 8.3. Exchange Structure and Key Topics

Over two days, the exchange featured plenary talks, breakout sessions, and panel discussions designed toÂ maximize cross-disciplinary learning and actionable outcomes. The first day opened with reflections onÂ the historical evolution ofÂ modeling inÂ radiation processing and regulatory science, highlighting milestones such asÂ the FAAâ€™s acceptance ofÂ flight simulators and previously benchmarked electron beam simulation models. The FDAâ€™s progressive adoption ofÂ computational modeling inÂ drug and device approvals was also discussed, illustrating how simulation has matured from anÂ academic tool toÂ aÂ cornerstone ofÂ regulatory science. Lessons from radiation oncology were presented, emphasizing the importance ofÂ rigorous metrology, traceability, and quality assurance inÂ treatment planning and clinical practice. Breakout sessions focused onÂ identifying gaps inÂ equipment capability, modeling competency, and regulatory requirements, with participants working collaboratively toÂ pinpoint barriers toÂ model adoption and opportunities for standardization.

The second day shifted toward practical applications and future directions. Industry and academic case studies showcased real-world examples ofÂ modeling inÂ device development, regulatory submissions, and clinical applications. AÂ mock FDA submission was presented, demonstrating how dose mapping validation using RayXpert simulation software can align computational results with physical measurements and meet ISO 11137 compliance. This example illustrated the potential for simulation data toÂ supplement orÂ even replace physical testing, provided that rigorous validation and benchmarking are performed. Collaborative sessions throughout the day were dedicated toÂ defining next steps, including the development ofÂ standards, engagement with regulatory agencies, and planning for future scientific exchanges.

### 8.4. Technical Insights and Case Studies

Technical insights from the event underscored the versatility and value ofÂ modeling inÂ radiation sterilization. Functional equivalence was central toÂ the goal ofÂ the scientific exchange, asÂ participants sought toÂ establish that modeling and simulation methods inÂ radiation sterilization can beÂ considered successful and acceptable when they reliably achieve the same safety and efficacy outcomes asÂ traditional physical testing, even ifÂ the specific approach orÂ details differ. Functional equivalence inÂ modeling means that aÂ process orÂ product achieves the intended outcome orÂ meets the required standards, even ifÂ the specific details orÂ pathway differ from the traditional orÂ expected approach. ToÂ visualize this, imagine anÂ airplane landing onÂ aÂ runway: itÂ does not matter whether the plane touches down exactly onÂ the center line orÂ slightly off-center, ifÂ the landing isÂ safe and successful. The essential goal isÂ aÂ safe arrival, not perfect alignment---just asÂ inÂ modeling, the critical measure isÂ whether the model delivers reliable, validated results, not whether every detail matches aÂ specific precedent.

Monte Carlo simulations, implemented through tools such asÂ RayXpert and MCNP, enable accurate dose mapping, shielding design, and validation against physical measurements. These methods are essential for ensuring device safety and efficacy, particularly inÂ scenarios where physical testing isÂ challenging orÂ impractical. The plenary talks included aÂ discussion about how Monte Carlo simulation can beÂ applied toÂ corrective action and preventive action (CAPA) processes, using the sterilization and simulation ofÂ cardiovascular stents asÂ anÂ example. Although the results shared were preliminary, they demonstrated the effectiveness ofÂ variance analysis, provided additional data toÂ support defect resolution, helped identify cases where corrective actions may beÂ necessary, and contributed toÂ setting limits for preventive actions.

The Modeling Software inÂ Practice presentation showcased aÂ range ofÂ simulation techniques used inÂ regulatory science and radiation sterilization. These included finite element analysis for structural mechanics, computational fluid dynamics for modeling fluid flow and heat transfer, and Monte Carlo methods for probabilistic modeling and radiation transport. The slides also highlighted applications such asÂ bench testing simulations, digital twin patient models, radiation shielding design, and dose mapping for medical devices. Together, these simulation approaches illustrate how advanced computational tools are driving innovation, improving safety, and supporting regulatory submissions inÂ the field.

### 8.5. Mock Q-Submission

With representatives posing asÂ aÂ FDA regulator, the simulation service provider, and the product manufacture, this demonstration provided aÂ detailed example ofÂ how advanced simulation tools, specifically RayXpert, may beÂ integrated into regulatory submissions for radiation sterilization. InÂ this case, Monte Carlo-based dose mapping was used toÂ model the radiation dose distribution within aÂ medical device, and the simulation results were rigorously validated against physical performance qualification (PQ) measurements. The comparative analysis showed that the deviations between simulated and measured dose values were functionally equivalent, demonstrating aÂ high degree ofÂ accuracy and reliability. This close alignment not only supports the credibility ofÂ the simulation tool but also meets the stringent requirements set forth byÂ ISO 11137, which governs standards for radiation sterilization.

ByÂ achieving such precise agreement between computational and physical data, the submission enhances regulatory confidence inÂ the use ofÂ modeling and simulation asÂ credible evidence. The mock Q-submission further illustrates how simulation can beÂ leveraged toÂ identify the bounds ofÂ anÂ uncertainty budget, where sensitivity studies onÂ key variables allows for understanding ofÂ their significance toÂ the overall results. These capabilities are especially valuable inÂ contexts where physical measurement isÂ challenging orÂ impractical. Overall, the example underscores the growing role ofÂ validated simulation inÂ streamlining regulatory review, improving safety assurance, and supporting innovation inÂ medical device sterilization.

### 8.6. Radiation Oncology Parallels

Rigorous quality assurance measures within the field ofÂ radiation oncology are performed atÂ regular intervals toÂ provide detailed knowledge ofÂ the radiation systems operations.

### 8.7. Regulatory Perspectives

Regulatory perspectives were aÂ focal point ofÂ the exchange. The FDAâ€™s recognition ofÂ computational modeling and simulation asÂ credible evidence inÂ device submissions was discussed inÂ detail, with recent guidance emphasizing risk-informed frameworks for model credibility, verification, and validation. The ASME V&V 40-2018 standard provides structured methods for assessing model credibility based onÂ context ofÂ use and risk, while the Medical Device Development Tools (MDDT) program streamlines regulatory submissions byÂ qualifying simulation tools and reducing the need for repeated validation. These initiatives collectively foster innovation, reduce regulatory burden, and promote confidence inÂ digital evidence.

### 8.8. Outcomes and Roadmap

The outcomes ofÂ the exchange were significant. Participants reached consensus onÂ the need for standardized methods ofÂ verification, validation, and uncertainty quantification. Key barriers toÂ adoption were identified, including insufficient training, inconsistent quality metrics, and limited regulatory acceptance. Action items emerging from the event included the development ofÂ standards for model qualification, the promotion ofÂ round-robin studies for cross-validation, and the integration ofÂ these priorities into the next CIRMS Needs Report toÂ guide NISTâ€™s future work.

### 8.9. Conclusion

InÂ conclusion, the 2025 Scientific Exchange atÂ NIST represented aÂ pivotal step toward integrating modeling and simulation into the practice ofÂ radiation sterilization. ByÂ building consensus, sharing technical expertise, and engaging with regulators, the community isÂ well-positioned toÂ advance innovation, safety, and efficiency inÂ sterilization practices. Continued collaboration and standards development will beÂ essential toÂ realizing the full potential ofÂ modeling asÂ aÂ robust, traceable tool for product validation and regulatory compliance.

## 9. Summary from Ileana Pazos

### 9.1. Information

- Scientific Exchange onÂ Modeling and Simulation for Radiation Sterilization
- September 16-17, 2025

### 9.2. Overview

- The modeling workshop was aÂ focused two-day scientific exchange onÂ modeling and simulation for radiation processing, held atÂ NIST inÂ September 2025.

- The event brought together government, industry, academia, and regulatory stakeholders toÂ address how mathematical modeling could beÂ better integrated into radiation sterilization processes.

#### 9.2.1. Workshop Structure and Participants

- The workshop featured morning presentations covering radiation simulation, mathematical methods, and radiation therapy perspectives, followed byÂ afternoon breakout sessions focused onÂ building credibility and developing standards.

#### 9.2.2. Key Problem Identified

- The central challenge addressed was that while mathematical modeling works well inÂ radiation oncology and other industries, itâ€™s not routinely used inÂ radiation sterilization workflows.

- The primary barrier isÂ economic â€” dose mapping costs $5,000â€“$10,000, while benchmarking aÂ mathematical model can cost $50,000â€“$100,000, making the investment difficult toÂ justify.

### 9.3. â€œSameâ€ Problem, except for dose and scale

#### 9.3.1. Focused clinical beam (2 GyÂ toÂ ~1 cmÂ region)

- **Objective:** deliver aÂ low dose precisely toÂ aÂ small, localized volume
- **Challenge:** complex modeling and simulation toÂ account for scattering, heterogeneity ofÂ tissues, beam shaping, and patient-specific anatomy
- **Verification:** relies heavily onÂ computational modeling, treatment planning systems, and imaging, with physical measurements used sparingly for quality assurance.

![clinical.png](./assets/clinical.png)

#### 9.3.2. Large-scale processing (20 kGy toÂ ~1 mÂ region)

- **Objective:** deliver aÂ very high dose uniformly toÂ aÂ large bulk product
- **Challenge:** relies onÂ uniformity and reproducibility across pallets orÂ containers, where modeling plays aÂ smaller role and physical dosimetry isÂ the foundation for process control.
- **Verification:** traceable physical dosimetry, with routine dose mapping and reproducibility checks toÂ confirm uniformity across the irradiation volume

![industrial.png](./assets/industrial.png)

### 9.4. Stakeholders: 47 registrants, 30 organizations

#### 9.4.1. Academia

- Georgia Institute ofÂ Technology
- Johns Hopkins University
- University ofÂ Pennsylvania

#### 9.4.2. Government

- FDA (U.S. Food and Drug Administration)
- CDRH (Center for Devices and Radiological Health)
- NIST (National Institute ofÂ Standards and Technology)
- NIH/NCI (National Institutes ofÂ Health / National Cancer Institute)
- Pacific Northwest National Laboratory (DOE national lab)
- Oak Ridge National Laboratory (DOE national lab)

### 9.5. Industry: Testing, Standards and Certification

- BSI (British Standards Institution, certification and standards)
- TÃœV SÃœD (testing, inspection, and certification services)
- Applied Research Associates, Inc. (engineering and applied science R&D)

#### 9.5.1. Industry: Medical Devices and Healthcare

- Medtronic (medical devices)
- Boston Scientific (medical devices)
- Johnson & Johnson (medical devices / healthcare products)
- Becton Dickinson (medical technology and diagnostics)
- Sartorius (biopharmaceutical and lab technologies)
- Meissner Consulting GmbH (biotech/consulting, single-use systems)
- StarFish Medical (medical device design and development)
- Triple Ring Technologies (medical and biotech engineering/consulting)

#### 9.5.2. Industry: Radiation Processing and Sterilization

- STERIS (infection prevention, sterilization solutions)
- STERIS AST (Applied Sterilization Technologies, contract sterilization)
- Sterigenics (contract sterilization)
- Steritek (contract sterilization services)
- BGS-US LLC (radiation sterilization, subsidiary ofÂ BGS Germany)
- Nordion (Cobalt-60 supply, irradiation technologies)
- Aerial (radiation processing / dosimetry)
- Reveam Inc (electron beam food sterilization)
- TRAD Tests and Radiations (dosimetry and radiation testing services)
- IBA (Ion Beam Applications, radiation therapy and industrial irradiation)
- Ebeam Consulting LLC (electron beam sterilization consulting)

### 9.6. Major Outcomes and Consensus

1. **Framework for Credibility**

   - The workshop established that any modeling approach must beÂ tied toÂ known dosimetry standards.

   - The consensus was toÂ build aÂ framework based onÂ continuous testing with dosimetry, combining virtual dosimetry with physical measurements rather than replacing them entirely.

2. **Three Key Application Areas**

   - Participants identified where modeling could make the biggest impact:

   - **Enhancing dosimetry:** Reducing physical dosimetry requirements inÂ performance qualification (PQ) submissions and guiding optimal dosimeter placement

   - **Supporting parametric release:** Using models toÂ set process parameter bounds without testing each scenario physically

   - **Advancing regulatory submissions:** Particularly through FDAâ€™s master file pilot program

3. **Regulatory Support**

   - AÂ significant finding was that regulators want toÂ see more simulation inÂ radiation sterilization - they just need proper justification.

   - The FDA representatives emphasized theyâ€™re supportive ofÂ modeling approaches when credibility isÂ demonstrated.

### 9.7. Technical Requirements Identified

The workshop highlighted several technical needs:

- Standardized phantoms for model validation
- Proficiency testing programs similar toÂ those inÂ radiation therapy
- Uncertainty quantification and sensitivity analysis protocols
- Competency assessment frameworks for modelers

### 9.8. Action Items

![flipchart-d.jpg](./assets/flipchart-d.jpg)
![flipchart-e.jpg](./assets/flipchart-e.jpg)

#### 9.8.1. Foundational

- Establish consensus standards and quality systems for verification, validation, and quality assurance, leveraging existing frameworks and organizations (e.g., ASTM, AAPM).

- Develop aÂ library ofÂ validated use cases with specific application contexts toÂ demonstrate credibility and impact.

- Create proficiency testing programs that incorporate modeling components toÂ benchmark performance and build confidence.

#### 9.8.2. Strategic Development

- Form aÂ CDRH-led working group toÂ develop aÂ specific use case and roadmap, including exploration ofÂ consortium funding mechanisms toÂ support project development.

- Develop aÂ white paper articulating the benefits ofÂ modeling from multiple stakeholder perspectives, serving asÂ aÂ unifying reference and outreach tool.

#### 9.8.3. Communication and Engagement

- Organize aÂ webinar toÂ summarize meeting outcomes, highlight action items, and engage broader stakeholders.

### 9.9. Challenges and Limitations

- The workshop identified that more focused time was needed toÂ hammer out implementation details.

- While the framework was established, significant work remains toÂ develop the specific standards and validation approaches needed for widespread adoption.

- The event successfully demonstrated strong collaboration potential between radiation sterilization and radiation therapy communities, with significant cross-pollination ofÂ ideas and approaches between the two fields.

### 9.10. White paper outline: Enhancing the Credibility ofÂ Simulation inÂ Sterilization

#### 9.10.1. Executive Summary

- Brief overview ofÂ the role ofÂ modeling and simulation inÂ sterilization.
- Meeting outcomes: consensus onÂ roadmap elements, credibility needs, and community priorities.
- Action plan: white paper, webinar, working group, and funding pathways.

#### 9.10.2. Introduction and Context

- Importance ofÂ modeling and simulation inÂ sterilization.
- Current challenges: lack ofÂ credibility, standardization, and regulatory alignment.
- Purpose ofÂ this white paper: define roadmap, align community, and build trust inÂ simulation.

#### 9.10.3. Overview ofÂ the Discussion

- Goals ofÂ the session: credibility, roadmap development.
- Key ideas discussed: publications, hackathons, academic engagement, proficiency testing.
- Summary ofÂ proficiency testing and consensus standards.

#### 9.10.4. Prioritizing Key Elements for aÂ Roadmap

- Proficiency testing and modeling proficiency guidelines.
- Consensus standards for methodology and validation.
- Quantifying uncertainty budgets.
- Sensitivity analysis and uncertainty qualification (UQ).
- Recommendation: focus onÂ aÂ single, well-defined use case.

#### 9.10.5. Developing aÂ Practical Roadmap

- Establishing aÂ standard reference case.
- Need for periodic validation and reproducibility checks.
- Characterization ofÂ phantoms and CAD drawing standards.
- Incorporating ancillary equipment and real-time data into models.
- Potential credentialing processes (lessons from radiation therapy).

#### 9.10.6. Building Credibility with Regulators

- Benefits ofÂ modeling for patients, industry, and regulators.
- Supporting regulatory submissions with simulation data.
- Importance ofÂ process control and traceability toÂ the virtual dose.
- Competency assessment toÂ build confidence.

#### 9.10.7. Leveraging Existing Resources and Standards

- Role ofÂ ASTM, AAPM, and other frameworks.
- Aligning with existing forums and standards organizations.
- Need for modeling proficiency guidelines.
- Exploring funding opportunities: grants, CDRH consortium support.

#### 9.10.8. Developing aÂ Use Case and Working Group

- Rationale for starting with aÂ simple, practical use case.
- Potential models toÂ build onÂ (e.g., syringe).
- Use case asÂ aÂ driver for credibility, engagement, and testing the roadmap.
- Establishment ofÂ aÂ working group under CDRH toÂ lead development.

#### 9.10.9. Engaging the Academic Community

- Motivating participation through publications, credit, and training opportunities.
- Integrating academic research with industry needs.
- Roadmap alignment toÂ ensure achievable goals.
- Webinars, workshops, and events toÂ sustain engagement.

#### 9.10.10. Final Thoughts and Next Steps

- Reaffirming patient health and safety asÂ the ultimate goal.
- Need for compromise, collaboration, and shared accountability.
- Draft and circulate white paper.
- Host webinar toÂ summarize outcomes and recruit participants.
- Form working group and define initial use case.
- Explore funding mechanisms (grants, consortium support).

## 10. Summary from Spencer Mickum

### 10.1. Information

- Scientific Exchange OnÂ Modeling and Simulation For Radiation Sterilization
- October 6, 2025

### 10.2. Scientific Exchange Highlights

Event took place September 16â€“17, 2025, atÂ the National Institute ofÂ Standards and Technology

#### 10.2.1. Interdisciplinary Collaboration

Experts from industry, academia, regulatory bodies, and standards organizations collaborated toÂ advance modeling for radiation sterilization.

#### 10.2.2. Consensus and Roadmap Development

Roughly 50 participants focused onÂ building consensus and shaping aÂ roadmap for robust, traceable modeling and simulation methods.

#### 10.2.3. Agenda

Over two days, the scientific exchange atÂ NIST featured plenary talks, breakout sessions, and panel discussions that traced the evolution ofÂ modeling inÂ radiation processing and regulatory science, explored lessons from radiation oncology, identified barriers and opportunities for standardization, showcased real-world case studies and aÂ mock FDA submission validating simulation against physical measurements, and concluded with collaborative planning for standards development, regulatory engagement, and future exchanges.

### 10.3. Technical Insights and Case Studies

#### 10.3.1. Functional Equivalence

Technical insights from the event highlighted the versatility and value ofÂ modeling inÂ radiation sterilization, emphasizing that functional equivalenceâ€”achieving the same safety and efficacy outcomes asÂ physical testingâ€”is central toÂ the acceptance ofÂ simulation methods.

#### 10.3.2. Modeling vsÂ Physical Testing

Monte Carlo simulations, using tools like RayXpert and MCNP, enable accurate dose mapping, shielding design, and validation against physical measurements, which are essential for ensuring device safety and efficacy, especially when physical testing isÂ impractical.

#### 10.3.3. Real-world Application Examples

Industry, academia, and government case studies presented byÂ Johnson & Johnson, Georgia Institute ofÂ Technology, and the National Institute ofÂ Health.

![medtronic.jpg](./assets/medtronic.jpg)

> Medtronic, â€œMedtronicâ€™s Endurant II/IIs Stent Graft System Receives CEÂ Mark For Use With ChEVAR Parallel Graft Technique, â€ 9 December 2016.

### 10.4. Regulatory Insights and Modeling

![mock-fda-a.jpg](./assets/mock-fda-a.jpg)
![mock-fda-b.jpg](./assets/mock-fda-b.jpg)
![mock-fda-c.jpg](./assets/mock-fda-c.jpg)

#### 10.4.1. Modeling asÂ Regulatory Evidence

AÂ mock FDA submission demonstrated how RayXpert simulation can beÂ integrated into regulatory filings for radiation sterilization. The primary objective ofÂ this mock FDA Q-submission isÂ toÂ demonstrate how simulation data aligns with Performance Qualification (PQ) measurements, thereby supporting the deviceâ€™s regulatory justification.

#### 10.4.2. Standards and Programs

The FDA recognizes simulation modeling asÂ credible evidence for device submissions, ensuring scientific rigor and credibility. ASME V&V 40-2018 standard and the MDDT program support reliable model credibility and streamline device submissions.

#### 10.4.3. Simulation for Compliance and Innovation

Mock submissions using validated simulations show how modeling aids regulatory compliance and supports innovative device development.

### 10.5. Outcomes and Future Roadmap

#### 10.5.1. Consensus onÂ Standardization

Despite success inÂ other sectors, modeling for industrial sterilization remains underutilized, slowing innovation and efficiency improvements. Participants agreed onÂ the importance ofÂ unified standards for verification, validation, and quantifying uncertainty toÂ ensure reliability.

#### 10.5.2. Identified Key Barriers

Absence ofÂ clear guidance and scientific consensus makes itÂ difficult toÂ implement modeling practices widely and consistently. Major barriers are training gaps, insufficient quality metrics, and regulatory acceptance, impacting progress and safety.

#### 10.5.3. Action Plan for Advancement

There isÂ aÂ strong demand for robust frameworks addressing verification, validation, and uncertainty quantification inÂ modeling.

Next steps involve developing standards, organizing round-robin studies, and embedding priorities inÂ strategic reports for innovation.

## 11. Summary from Cody Wilson

### 11.1. Breakout session on Traceability and Validation

We began the session with an overview from Florent K about how validation is built into the radiation processing system. Describing IQ/OQ/PQ and routine dose monitoring. The purpose was to introduce the whole group to the practices of the industry.

Next, we asked where the members thought simulation could benefit that process. Below is a summary of their input.

#### 11.1.1. Enhancing and Replacing Dosimetry and Validation Activities

- Replacement/Reduction of Physical Dosimetry: Modeling can potentially replace physical dosimeters in Performance Qualification (PQ) and reduce the regulated burden once fully implemented. It can also assist PQ to replace dosimeters by providing critical data.

- Strategic Dosimeter Placement: Simulation can be used to help place dosimeters more effectively and ensure coverage.

- Comparison and Equivalency: Modeling can be used to compare different geometries and demonstrate equivalency between different sterilization setups or processes.

- Post-Validation Support: It is useful for after reloading validation and for making adjustments such as a change simulation for product changes.

#### 11.1.2. Supporting Parametric Release and Routine Operations

- Parametric Release: Modeling supports Parametric release routing dosimetry and offers Parametric release support in X-ray, enabling the release of products based on process parameters and model predictions rather than solely on product-specific dosimetry.

- Proficiency and Optimization: It can be used for a Proficiency test and to find the easiest system gamma/xray, then extend to broader applications.

#### 11.1.3. Advancing Regulatory Submission and Standardization

- Master File Submissions: Modeling can be used for master file submissions, streamlining the regulatory process by providing robust technical justification.

- Primary Standard: The ultimate goal is to establish Simulation as a primary standard to dosimetry, elevating its role from a supporting tool to a fundamental basis for validation.

- In essence, these suggestions highlight modeling as a powerful tool to increase efficiency, reduce testing requirements, optimize processes, and provide robust scientific justification for regulatory compliance and product release in radiation sterilization.

### 11.2. Breakout session on establishing confidence in models

Strategies for Instilling Confidence in Radiation Processing Models
The core strategy for increasing confidence in radiation processing models involves a rigorous combination of sensitivity analysis, data collection, and defining clear applicability boundaries.

#### 11.2.1. Address Product Positioning Risk

- Risk: The model's predictions are sensitive to the chosen product positioning within the radiation field.

- Mitigation: Perform a sensitivity analysis on every adjustable aspect of the product's positioning (the "degrees of freedom").
Outcome: Use the analysis results to recommend clear restraints or limits on positioning variability that the model can handle reliably.

#### 11.2.2. Ensure System State Monitoring

- Risk: The model's accuracy degrades because the actual system state (parameters like temperature, beam current, etc.) is not being monitored precisely enough.

- Mitigation: Conduct a sensitivity analysis on all critical, observable parameters.
Outcome: Based on the analysis, develop periodic recommendations for resetting the system or recalibrating the model inputs to ensure the system state remains within acceptable, low-uncertainty bounds.

#### 11.2.3. Improve Model Accuracy

- Risk: The model's fundamental structure or parameters are not sufficiently accurate to predict results reliably.

- Mitigation: Assemble a sufficient amount of ground truth data. This includes data collected from the actual process and, crucially, data derived from independently designed engineered phantoms that provide clear, unambiguous validation points.

#### 11.2.4. Define Model Limits

- Risk: Users might apply the model to scenarios or products that are beyond its inherent capability, leading to incorrect predictions.

- Mitigation: Conduct a thorough study of the limits of the model itself (e.g., maximum dose, material types, density range, geometry complexity).
Outcome: Create clear recommendations outlining the model's applicability and its boundaries so that users know precisely when and where the model is valid.

### 11.3. Breakout session onÂ Embedding Reality into Models

<!-- ![image](./assets/notes-wilson-a.png) -->

- Our definition ofÂ reality: inputs, feasibility, and applications conditions
- Community for developing and executing roadmap
  - Professional organizations
  - Medical device manufacturers
  - Service providers
  - Equipment providers
  - Modelers
  - Regulators
  - Academia and government
  - Standards community

<!-- ![image](./assets/notes-wilson-b.png) -->

**Philosophy:** inform and update regulators about roadmap and milestones for each effort.

| Efforts                                                                                                 | Roadmap                                                          |
| :------------------------------------------------------------------------------------------------------ | :--------------------------------------------------------------- |
| Start with a standard reference case (physics phantom, calibration set, etc)                            | Form a group of contributors                                       |
| Periodic activities to aligning system parameters to validate simulation                                | Expand current OQ activities                                     |
| Characterize uncertainties                                                                              | Survey knowledge of experienced users for drivers of uncertainty |
| Specify needs for CAD drawings (with uncertainty)                                                       | Collect input from modelers and medical device suppliers         |
| Guidance on studies testing accuracy for facility specific products                                     | Work through modelers and standards community                     |
| Develop different paths/roadmaps for electrons and photons                                              | Leverage professional standards community to form realistic path |
| Address inputs needed for model validation with real-time data                                          |                                                                  |
| Evaluate need for ancillary equipment to enable model accuracy to real-world conditions (CT Scans, etc) |                                                                  |
| Credentialing process                                                                                   | Empower an academic or government institution                    |
